Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials

Chen, Ronald C.; Chang, Peter; Vetter, Richard J.; Lukka, Himansu; Stokes, William A.; Sanda, Martin G.; Bruner, Deborah Watkins; Reeve, Bryce B.; Sandler, Howard M.

doi:10.1093/jnci/dju132

Cited by 92 publications

(87 citation statements)

References 100 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pain is the most frequently observed symptom in men with mCRPC and appropriate analgesia is often underutilised. 13,37 In comparison to other men with prostate cancer, those with mCRPC report significantly poorer QoL, due to pain, fatigue, and decreased physical activity. 38 These areas of concern need to be captured fully when palliation is a therapeutic aim.…”

Section: Discussionmentioning

confidence: 99%

Patient-reported outcomes in metastatic castration-resistant prostate cancer

2016

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Patient-reported outcomes in metastatic castration-resistant prostate cancer

2016

View full text Add to dashboard Cite

“…17). Efforts have been undertaken to identify the key symptoms to measure in several malignant diseases, such as prostate, head and neck, and ovarian cancers (11,18,19), and measurement tools continue to be developed and refined.…”

Section: Disease-related Symptomsmentioning

confidence: 99%

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Kluetz

Slagle

Papadopoulos

et al. 2016

Clinical Cancer Research

269

222

View full text Add to dashboard Cite

Cancer clinical trials have relied on overall survival and measures of tumor growth or reduction to assess the efficacy of a drug. However, benefits are often accompanied by significant symptomatic toxicities. The degree to which a therapy improves disease symptoms and introduces symptomatic toxicity affects how patients function in their daily lives. These concepts are important contributors to health-related quality of life (HRQOL). In this article, we discuss patient-reported outcome (PRO) assessment in cancer trials and challenges relying solely on static multi-item HRQOL instruments. We propose focusing on three separate measures of well-defined concepts: symptomatic adverse events, physical function, and disease-related symptoms, which are key contributors to the effect of a therapy on HRQOL. Separate measures of these three concepts may facilitate the incorporation of emerging contemporary instruments that can tailor the PRO assessment strategy to different trial contexts. Irrespective of the PRO measures used, continued improvement in trial design and conduct is crucial to decrease missing data and optimize the quality of PRO information. International stakeholder collaboration and continued research into optimal practices for PRO and other clinical outcome assessments are necessary to advance a common framework for generating and reporting rigorous patient-centered data from cancer clinical trials.

show abstract

“…Prostate cancer and its treatments (radical prostatectomy, radiotherapy, and hormonal therapy) specifically cause a set of sexual, urinary, and bowel symptoms -and multiple validated instruments exist to measure these (Table 3) [19].…”

Section: Prostate Cancermentioning

confidence: 99%

Patient-reported outcomes in cancer survivorship

Gordon

Chen

2017

Acta Oncologica

Self Cite

View full text Add to dashboard Cite

Background: There are currently 33 million cancer survivors worldwide. With improvements in early cancer detection and treatments, patients are living longer -and it is well-recognized that many survivors develop short-and long-term physical, psychosocial and spiritual effects as a result of their diagnoses and treatments. There is increasing awareness of the importance of using patient-reported outcomes (PROs) to accurately assess these effects in cancer survivors. Validated patient-reported outcome instruments: Traditionally, physicians have assessed the acute and late side effects of cancer treatments with standardized scales such as the CTCAE. However, multiple studies have demonstrated that PROs more accurately capture patient symptoms than physician assessment. In this article we describe frequently used, validated, general and cancer-specific PRO instruments that assess symptoms. We describe additional PRO instruments that assess unmet needs, interpersonal relationship issues, and psychosocial and financial problems. Published studies using these instruments have identified issues commonly faced by cancer survivors worldwide. Discussion and summary: While PROs are increasingly used in research, further efforts are needed to integrate PRO assessment into routine clinical care, so that timely and accurate assessments can translate into better management of issues -ultimately improving the lives of cancer survivors.

show abstract

Recommended Patient-Reported Core Set of Symptoms to Measure in Prostate Cancer Treatment Trials

Cited by 92 publications

References 100 publications

Patient-reported outcomes in metastatic castration-resistant prostate cancer

Patient-reported outcomes in metastatic castration-resistant prostate cancer

Focusing on Core Patient-Reported Outcomes in Cancer Clinical Trials: Symptomatic Adverse Events, Physical Function, and Disease-Related Symptoms

Patient-reported outcomes in cancer survivorship

Contact Info

Product

Resources

About